BTK is a deeply validated CLL target with intense competition and meaningful white space in resistance, safety, and fixed-duration combinations.

JAK2 is a validated myelofibrosis target where differentiation depends on clinically meaningful subgroups and endpoints.

FLT3 is a highly validated AML target with active opportunity in combinations, maintenance, and resistance-focused development.

IDH1 is a focused, clinically validated AML target with remaining opportunity in combination and sequencing strategy.

NTRK1 is attractive in fusion-positive solid tumors, but evidence quality depends on precise biomarker filtering.

CDK4 is a highly validated breast cancer target with remaining opportunity in selectivity, sequencing, and endocrine-combination strategy.

PARP1 is a validated ovarian cancer target, with new opportunity concentrated in biomarker precision and combination strategy.

AR is one of oncology’s most validated targets, but new value requires resistance-focused or modality-differentiated strategy.

ESR1 is a foundational breast cancer target with continuing opportunity in endocrine resistance and oral degrader strategies.

PIK3CA is a validated breast cancer target with high clinical relevance and intense safety/differentiation pressure.

MET is a high-interest NSCLC target, but strategic value depends on biomarker precision and indication-specific competitive mapping.

ROS1 is a validated but specialized NSCLC target where precision evidence and differentiation matter more than raw target popularity.